Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:TYME Tyme Technologies (TYME) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Tyme Technologies Stock (NASDAQ:TYME) 30 days 90 days 365 days Advanced Chart Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Tyme Technologies alerts:Sign Up Key Stats Today's Range$0.29▼$0.3250-Day Range$0.24▼$0.3552-Week Range$0.22▼$1.14Volume2.68 million shsAverage Volume1.01 million shsMarket Capitalization$53.50 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewTyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.Read More… 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Receive TYME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tyme Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address TYME Stock News HeadlinesVirginia Holocaust Museum unveiling exhibit utilizing AI technology to tell survivors’ storiesOctober 31 at 11:13 PM | msn.comFinfra Partners With Tyme Group To Drive Indonesia’s Embedded Lending BoomOctober 29, 2024 | za.investing.com625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.November 2, 2024 | Crypto Swap Profits (Ad)43 Home Products That Are So Worth It, You Won't Regret The SplurgeOctober 24, 2024 | msn.comCreating a Winter Herb Garden IndoorsOctober 23, 2024 | msn.comFresh Thyme brings Afresh AI-tech to deli, prepared foods departmentsOctober 23, 2024 | finance.yahoo.comHerb Gardening During Winter: Cultivating Fresh Flavors Indoors and OutdoorsOctober 17, 2024 | msn.comDetermining Geographic Origin’s Influence on Thyme Aroma Profile using GC-TOFMSOctober 11, 2024 | msn.comSee More Headlines TYME Stock Analysis - Frequently Asked Questions How were Tyme Technologies' earnings last quarter? Tyme Technologies, Inc. (NASDAQ:TYME) released its quarterly earnings results on Monday, November, 8th. The company reported ($0.03) EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.03. What other stocks do shareholders of Tyme Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tyme Technologies investors own include NIO (NIO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Tonix Pharmaceuticals (TNXP), SCYNEXIS (SCYX) and Palantir Technologies (PLTR). Company Calendar Last Earnings11/08/2021Today11/02/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:TYME CUSIPN/A CIK1537917 Webwww.tymeinc.com Phone(212) 461-2315FaxN/AEmployees17Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,630,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-28.30% Return on Assets-26.21% Debt Debt-to-Equity RatioN/A Current Ratio14.06 Quick Ratio14.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.47 per share Price / Book0.66Miscellaneous Outstanding Shares172,207,000Free Float143,104,000Market Cap$53.50 million OptionableOptionable Beta0.93 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:TYME) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tyme Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tyme Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
